Scientists in Britain have identified a genetic mutation involved in certain types of lung cancer and said the breast cancer drug Herceptin might work in patients who have it. The gene called ERBB2 is linked to four percent of non-small-cell lung cancers (NSCLC), which account for about 75 percent of all cases of the deadly disease. "ERBB2 is one of a series of biological switches in our cells that plays a vital role in controlling whether cells survive and proliferate," Dr Andy Futreal, a co-leader of the Cancer Genome Project which found the gene, said on Wednesday. "When the ERBB2 protein is switched on, it talks to other molecules in the cell to initiate a cascade of changes that alter how cells grow." Some mutations in the gene result in uncontrolled cell division, or cancer. ERBB2 also plays a role in some cases of breast cancer which are treated with Herceptin, or trastuzumab. The drug made by U.S. group Genentch Inc. and Switzerland's Roche Holding AG dampens the activity of ERBB2. Herceptin was designed to treat cancers in patients whose tumours over-express the growth-promoting HER-2 gene. It is suitable for about a quarter of breast cancer patients. "We have an existing drug that works against the overactive ERBB2 protein," Futreal, who reported the findings in the science journal Nature, said. --More 2117 Local Time 1817 GMT
